-
Velaresol
- names:
5-(2-formyl-3-hydroxyphenoxy)pentanoic acid
- CAS号:
77858-21-0
MDL Number: - MF(分子式): C12H14O5 MW(分子量): 238.239
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|
| 中文别名 | 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid |
| 英文别名 | Velaresol; BW 12C79; BW-12C79; BW12C79; BW 12C; BW-12C; BW12C. |
| CAS号 | 77858-21-0 |
| Inchi | InChI=1S/C12H14O5/c13-8-9-10(14)4-3-5-11(9)17-7-2-1-6-12(15)16/h3-5,8,14H,1-2,6-7H2,(H,15,16) |
| InchiKey | NSUDGNLOXMLAEB-UHFFFAOYSA-N |
| 分子式 Formula | C12H14O5 |
| 分子量 Molecular Weight | 238.239 |
| 溶解度Solubility | |
| 性状 | Yellow solid powder |
| 储藏条件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 产品说明 | Velaresol(CAS:77858-21-0):仅限应用于工业或者科学研究过程中非医疗目的,不应用于人类或动物的临床诊断以及治过程疗,该产品非药用,非食用。 |
| Introduction | Velaresol, also known as BW12C or BW12C79, is a oxyhaemoglobin stabilizer. Velaresol stabilizes oxyhaemoglobin also protect sickle cells against calcium-mediated dehydration.Velaresol causes a reversible left-shift of the oxygen saturation curve (OSC) and tissue hypoxia. |
| Application1 | |
| Application2 | |
| Application3 |
| [1]Philip PA, Thompson CH, Carmichael J, Rea D, Mitchell K, Taylor DJ, Stuart NS, Dennis I, Rajagopalan B, Ganesan T, et al. A phase I study of the left-shifting agent BW12C79 plus mitomycin C and the effect on the skeletal muscle metabolism using 31P magnetic resonance spectroscopy. Cancer Res. 1993 Dec 1;53(23):5649-53. PubMed PMID: 8242619. |
| [2]Trudel M, De Paepe ME, Chrétien N, Saadane N, Jacmain J, Sorette M, Hoang T, Beuzard Y. Sickle cell disease of transgenic SAD mice. Blood. 1994 Nov 1;84(9):3189-97. PubMed PMID: 7949191. |
| [3] Gibson JS, Khan A, Speake PF, Ellory JC. O2 dependence of K+ transport in sickle cells: the effect of different cell populations and the substituted benzaldehyde 12C79. FASEB J. 2001 Mar;15(3):823-32. PubMed PMID: 11259401. |
| [4] Propper DJ, Levitt NC, O'Byrne K, Braybrooke JP, Talbot DC, Ganesan TS, Thompson CH, Rajagopalan B, Littlewood TJ, Dixon RM, Harris AL. Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer. Br J Cancer. 2000 Jun;82(11):1776-82. PubMed PMID: 10839290; PubMed Central PMCID: PMC2363221. |
| [5] Muzyamba MC, Speake PF, Gibson JS. Oxidants and regulation of K(+)-Cl(-) cotransport in equine red blood cells. Am J Physiol Cell Physiol. 2000 Oct;279(4):C981-9. PubMed PMID: 11003578. |
6: Gibson JS, Speake PF, Ellory JC. Effect of the substituted benzaldehyde 12C79 on Cl--dependent K+ influx in human red blood cells. Pflugers Arch. 1999 Feb;437(3):498-500. PubMed PMID: 9914409.7: Keidan AJ, Sowter MC, Johnson CS, Marwah SS, Stuart J. Pharmacological modification of oxygen affinity improves deformability of deoxygenated sickle erythrocytes: a possible therapeutic approach to sickle cell disease. Clin Sci (Lond). 1989 Apr;76(4):357-62. PubMed PMID: 2714049.8: Wootton R, Stammers DK, White RD. Reduction in potency and reversal of left-shifting activity of BW12C with the major and minor components of chicken hemoglobin. FEBS Lett. 1986 Dec 1;209(1):129-33. PubMed PMID: 3803572.9: Stevens G, Hill SA, Joiner MC, Joiner B, Johns H, Williams K, Denekamp J, Nethersell AB. The effect of BW12C on the radiosensitivity and necrosis of murine tissues and tumours. Australas Radiol. 1994 Aug;38(3):199-203. PubMed PMID: 7945114.10: Falk SJ, Ramsay JR, Ward R, Miles K, Dixon AK, Bleehen NM. BW12C perturbs normal and tumour tissue oxygenation and blood flow in man. Radiother Oncol. 1994 Sep;32(3):210-7. PubMed PMID: 7816940.1
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


